FIGURE 4.

Interleukin-17A treatment decreases PRTN3 expression hBMECs. Western blot analysis of ZO-1, Occludin, Claudin-5, and VE-Cadherin extracted from IL-17A untreated hBMECs and IL-17A treated hBMECs with or without the presence of Proteasome inhibitor MG-132 (A) or autophagy inhibitor chloroquine (B). β-Actin was used as the loading control. (C) The qPCR analysis of PRTN3 transcription in hBMECs treated by multiple dosages of IL-17A (0, 1, 5, 10, and 20 ng/mL). GAPDH was used as the internal reference. Data were presented as mean ± SD from three independent experiments. **p < 0.01 and ***p < 0.001 by one-way ANOVA analysis. (D) Western blot analysis of PRTN3 in hBMECs in response to multiple dosages of IL-17A. β-Actin was used as the loading control.